The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
Kathleen M. Fox, MHS, PhD
Advertisement
Articles by Kathleen M. Fox, MHS, PhD
Advertisement
Latest Updated Articles
- Metastatic Non–Small Cell Lung Cancer: Costs Associated With Disease Progression
Published: September 15th 2008 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
2
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
3
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
4
White House to Announce Second Drug Pricing Deal as AstraZeneca Joins TrumpRx
5
